In this interview, we spoke with Justin Lathia about sexual dimorphism in glioblastoma, including his talk on sex differences in microglia and the glioma microenvironment.
This week we look at NurOwn® for multiple sclerosis, a combination therapy failing to meet primary endpoint for glioblastoma and warnings from the US FDA.
A valuable cache of brain cancer biomedical data, termed REMBRANDT, has been made freely accessible to researchers worldwide.
Interim results from a Phase III trial of DCVax®-L have revealed that the vaccine could be safe in glioblastoma patients and may extend survival.
From novel biomarkers, to the potential use of the Zika virus as a tumor treatment, read our round-up of the biggest neuro-oncology news from the last year as we mark World Cancer Day.
Combined-modality hypofractionated radiotherapy for elderly patients with glioblastoma: setting a new standard
Discover how combined-modality hypofractionated radiotherapy could become the new standard of care for elderly patients with glioblastoma in this editorial from Future Science OA.
Researchers have demonstrated that the enzymatic activity of R5 receptor-type protein tyrosine phosphatases is a requisite for the maintenance of stem cell properties and tumorigenicity in glioblastoma cells and could be a promising drug target for treatment.
In a new study published in Scientific Reports, the investigators also reported a higher risk of glioblastoma in Alzheimer’s patients.
This review explores commonly used experimental models of GBM, recent improvements to these models and strategies for developing advanced models.
A new first-of-its-kind study will assess Zika virus as a tool to target glioblastomas, one of the most challenging cancers to treat.